Even as far as we’ve come in modern medicine, there are still several things we don’t understand. A renewed emphasis on genomics is transforming the field, where DNA sequencing is being employed to better characterize diseases and assist doctors with treatment options.

7investing lead advisor Simon Erickson has found an important enabler of this long-term developing trend. His Top Stock for December has an incredible long-term vision and is innovating quickly, making it an excellent opportunity for growth-style investors.

Transcript

As much as we know about modern medicine, we’re still surrounded by a fog of uncertainty. Several of the fundamental drivers of diseases are things we either can’t see or don’t understand.

I’m 7investing lead advisor Simon Erickson, and my top stock for December is an innovator who’s clearing the air for the future of American health care.

America spends more than $4 trillion annually on health care. That’s more than $10,000 per person each and every year! And more than a quarter of this spend is going toward tests which are considered to be either medically unnecessary or redundant.

But what if we could better understand those fundamental drivers of diseases, and then correlate them to the patients that are showing the symptoms? If we could, we could not only save a lot of money, but also improve the patient outcomes in the long term.

The company that I’m recommending this month is showing signs of doing exactly that. It’s led by a visionary management team, it’s building out solid competitive advantages, and it’s winning favor with long term investors.

To see the name of the company that I’m recommending, as well as all seven of our top stock market recommendations each and every month, click on the link at the end of this video to get started with 7investing today.

We’re here to empower you to invest in your future. We are 7investing.